Bitcoin plunged to a seven-month low near $80,000, mirroring a broader market retreat from riskier assets due to stretched tech valuations and interest rate uncertainty. Analysts warn of steeper losses if the $82,000 support breaks, though some see signs of dip-buying. Ether also experienced significant declines.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,
June 1, 2026